In developing our products, the specificity of immune boosting is determined by the nucleotide sequence of the disease DNA which also encodes several disease specific antigens - these antigens are specific to the causative agent of the disease. For chronic, infectious diseases the recombinant antigens are derived from the target virus and/or intracellular bacteria in order to boost the immune system which in turn will eliminate the infected cells.
For cancer, the antigens are derived from genes that are specifically expressed in cancer cells in order to boost the immune system, which in turn will cancer cells. For allergy, the antigens are derived from recombinant allergens to boost the immune system and balance the pathogenic immune response.
Our Active Pharmaceutical Ingredient (API) discovery program, supported with two proprietary software products. Our ANTIGENeering software assists the processes for the design, preparation and testing of pDNA-encoded antigens. Our eMINER software provides a rapid and >85% reliable in-silico prediction of the antigen-derived epitopes. These support technologies assist the development of our personalized Immune Therapy Platform
As an example in the case of our lead product candidate HIV vaccine, DermaVir's API, a single pDNA was ANTIGENeered for the regulated expression of thirteen complete and two non-functional HIV protein antigens. These proteins self assemble into a Virus Like Particle (VLP) which structurally resembling the HIV. We have introduced multiple irreversible safety features by genetic modifications including the complete impairment of integration and reverse transcription. Our epitope analysis with eMINER predicts that DermaVir can express over 3,000 high-affinity T cell epitopes. DermaVir has the broadest antigen repertoire among HIV vaccine candidates.